Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05688969 · ClinicalTrials.gov registry record · NA
Mechanisms of Anabolic Osteoporosis Therapy
A NA study of Osteoporosis, Postmenopausal, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT05688969: Recruiting NA study of Osteoporosis, Postmenopausal, sponsored by Massachusetts General Hospital.
NCT05688969 is a NA study of Osteoporosis, Postmenopausal that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 16 participants, below the 2,733-participant average among 12 other Osteoporosis, Postmenopausal trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05688969, a NA study of Osteoporosis, Postmenopausal, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to investigate the effect of romosozumab on bone cells during early and late phases of treatment.
Primary Outcome
The investigators are testing the mechanistic hypothesis that romosozumab treatment increases osteoblast progenitor cell numbers at early, but not late, treatment time points.
Conditions Studied
Interventions
- OTHER early versus late biopsy
Study Locations (1)
Massachusetts
- Mass General Brigham - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-06-14 |
| Est. Completion | 2028-12 |
| Phase | NA |
What NCT05688969 shows while recruiting
NCT05688969 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 2,733-participant average among 12 other Osteoporosis, Postmenopausal trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Osteoporosis, Postmenopausal appearing as the primary indexed condition, and to 1 intervention - of which early versus late biopsy is the first listed.
NCT05688969 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05688969 about?
NCT05688969 is a clinical study titled "Mechanisms of Anabolic Osteoporosis Therapy". The aim of this study is to investigate the effect of romosozumab on bone cells during early and late phases of treatment.
What is the current status of trial NCT05688969?
This trial is currently recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2023-06-14. Estimated completion is 2028-12.
What conditions does trial NCT05688969 study?
This clinical trial studies the following conditions: Osteoporosis, Postmenopausal.
What interventions are being tested in trial NCT05688969?
The interventions under investigation include: early versus late biopsy (OTHER).
Who is sponsoring clinical trial NCT05688969?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05688969 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis, Postmenopausal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05688969's enrollment target sits among peer trials
16 13th of 12 the lowest of 12 other Osteoporosis, Postmenopausal trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoporosis, Postmenopausal trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Combined Anabolic Therapy
RECRUITING · Phase 4
-
Comparative Efficacy, Safety, PK, and Immunogenicity Study
ACTIVE NOT RECRUITING · Phase 3
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Romosozumab Use to Build Skeletal Integrity
ACTIVE NOT RECRUITING · Phase 4
-
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
ACTIVE NOT RECRUITING · Phase 4
-
Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI